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Tomography–Guided
Percutaneous Lung Biopsy
Specimens
To the Editor—We read with great in-
terest the article by Lass-Flo¨rl et al. [1]
about the utility of examination of CT-
guided lung biopsy specimens for diag-
nosis of invasive fungal infection in im-
munocompromised patients. For greater
appreciation and to generalize the article’s
findings, some issues need additional
clarification.
First, CT-guided transthoracic needle
biopsy of the lung has become a common
procedure to elucidate the nature of pul-
monary nodules [2]. The diagnostic per-
formance of this procedure for tumors de-
pends on the size, location, and radiologic
and histologic characteristics of the lesion,
and the procedure is reported to have high
sensitivity and specificity for malignancy
[3]. At present, studies of the diagnostic
accuracy of this approach are scarce in the
context of invasive pulmonary mycosis.
The technique is reported to have a
considerable rate of complications in sev-
eral reports, and we have some concern
regarding potentially severe complications
in the studied population. Although pneu-
mothorax is reported to occur in 8%–60%
of patients, it seldom requires drainage
(1%–13% of patients) among persons
who present with pulmonary nodules [4–
6]. Use of a thoracic tube to treat pneu-
mothorax in immunocompromised pa-
tients may constitute an important risk
factor for infection. Major hemorrhage,
which is considered to be a very rare ad-
verse event following CT-guided needle
biopsy, may also constitute a relevant haz-
ard in invasive pulmonary aspergillosis.
Patients with hematologic malignancies
and invasive pulmonary mycosis have an
increased risk of developing bleeding com-
plications due to both thrombocytopenia
and hypervascularization of the lesion.
Therefore, it would be of great interest to
have additional detailed data about the
rate of complications in the described im-
munocompromised population.
Second, thrombocytopenia is common
in patients with hematologic malignancies.
The described technique is contraindi-
cated for patients with platelet counts
!50,000 platelets/mL. We are concerned
that there was no information about plate-
let counts and transfusion. In our opinion,
Lass-Flo¨rl et al. [1] should have provided
the percentage of patients with hemato-
logic malignancies for whom this diag-
nostic approach would have been contra-
indicated and who required platelet
transfusion.
Third, the authors documented an un-
expectedly high proportion of patients
with Zygomycetes infection (13 [21.3%]
of 61 patients). This finding is of great
concern and could have major conse-
quences in clinical practice, because drugs
that are commonly used for these patients
(e.g., voriconazole and echinocandins) are
not effective against these fungi. There-
fore, we asked ourselves whether the high
rates of Zygomycetes infection observed
by the authors could be associated with
local epidemiologic features, prophylactic
regimens, and/or greater diagnostic ac-
curacy of their approach. The generally
observed increase in the rate of zygomy-
cosis seems to be associated with the type
of prophylaxis administered [7, 8], as re-
flected by the relationship between the use
of voriconazole prophylaxis and the in-
creased frequency of zygomycosis docu-
mented in several recent reports [9, 10].
Additional information on local, specific
fungal epidemiology, the prophylactic reg-
imens used for solid-organ transplant re-
cipients, and hematologic malignancies in
the studied population should have been
provided to clarify the high rate of Zy-
gomycetes infection.
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Reply to Garzoni
and Dumont
To the Editor—We thank Garzoni and
Dumont [1] for their correspondence and
appreciate their interest in our study re-
garding the value of CT-guided percuta-
neous lung biopsies [2] for diagnosis of
fungal infection.
Invasive fungal infection is a major
cause of morbidity and mortality in im-
munosuppressed patients. Case-fatality
rates range from 30% to 80% among neu-
tropenic patients, and deaths result, at
least in part, from difficulties in obtaining
a reliable diagnosis [3]. However, only an
accurate diagnosis allows for a specific
therapy directed against the cause of the
infiltrates, allows elimination of unnec-
essary and potentially toxic antimicrobial
agents, and facilitates a more rational ap-
proach to the treatment of these critically
ill patients. Tissue samples represent the
most satisfactory specimens for use in di-
agnosis of invasive fungal infection [4].
Thus far, there has been no doubt that
performance of CT-guided percutaneous
lung biopsy in immunocompromised pa-
tients is a risk for potential complications.
Contraindications, such as pulmonary
hemorrhage with hemoptysis and infec-
tion, may account for these risks [5]. In
our cohort of 61 patients, there were no
emergencies that required treatment of he-
moptysis, although 1 patient experienced
pneumothorax requiring chest tube place-
ment. The timing of lung biopsy depended
on the patient’s condition. The interval
from radiologic diagnosis to biopsy inter-
vention was 9 days (range, 4–22 days).
Biopsy specimens were not obtained
during severe neutropenia (absolute neu-
trophil count, !500 cells/mL) or throm-
bocytopenia (platelet count, !50,000
platelets/mL). Five patients received plate-
let transfusions.
Zygomycetes infections are non-Asper-
gillus mold infections and are important
causes of morbidity and mortality among
immunocompromised patients [6]. An
alarming increase in the number of case
reports of zygomycosis have been noted
among patients with cancer over the past
decade [7]. However, center-to-center dif-
ferences occur, and there is a lack of
knowledge regarding the reasons for this
epidemiologic shift. One proposed pre-
disposing factor is the widespread use of
voriconazole as prophylaxis for patients
who have hematologic malignancies or
who have undergone hematopoietic stem
cell transplantation. Conversely, some re-
searchers have suggested that the associ-
ation is not causative but rather a reflec-
tion of changes in the host’s immune
constitution or time at risk while receiving
immunosuppressive drugs [8]. In our
health care center, prophylaxis and treat-
ment strategies accord with international
guidelines and recommendations [9, 10].
Patients who have hematologic malignan-
cies and/or who have undergone alloge-
neic or autologous stem cell transplanta-
tion received standard prophylaxis with
fluconazole (400 mg/day). For empirical,
preemptive treatment of invasive fungal
infection, therapy was switched to either
a lipid formulation of amphotericin B or
voriconazole. Overall, the rate of infection
due to Zygomycetes increased in our hos-
pital, as well as in other health care centers,
indicating the necessity for a powerful
means of diagnosis to reduce the high
mortality for this condition.
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